9,702 results match your criteria: " Taiwan; Research Center of Environmental Education and Sustainable Technology[Affiliation]"

Validation of a method for the determination of Aderamastat (FP-025) in KEDTA human plasma by LC-MS/MS.

J Chromatogr B Analyt Technol Biomed Life Sci

September 2024

Department of Clinical Pharmacy & Pharmacology, University Medical Center Groningen, Groningen, the Netherlands; Department Pharmaceutical Analysis, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, the Netherlands.

Aderamastat (FP-025) is a small molecule, selective matrix metalloproteinase (MMP)-12 inhibitor, under development for respiratory conditions which may include chronic inflammatory airway diseases and pulmonary fibrosis. To support evaluation of the pharmacokinetic parameters of Aderamastat in humans, we developed and validated a high-performance liquid chromatography tandem mass spectrometry (LC-MS/MS) analytical method for the quantification of Aderamastat in human plasma. This assay was validated in compliance with the Food and Drug Administration (FDA) Good Laboratory Practice Regulations (GLP) and European Medicines Agency (EMA) guidelines.

View Article and Find Full Text PDF

Background: The perioperative administration of low-dose ketamine has shown potential in postoperative pain management, opioid sparing, and enhancing pain control. This study aimed to investigate the impact of low-dose ketamine on processed electroencephalography (EEG) signals during anesthesia.

Methods: Forty patients with American Society of Anesthesiologists physical status I-II undergoing elective gynecological surgery were enrolled.

View Article and Find Full Text PDF

Assessment of Thrombectomy versus Combined Thrombolysis and Thrombectomy in Patients with Acute Ischemic Stroke and Medium Vessel Occlusion.

Radiology

August 2024

From the Neuroendovascular Program, Massachusetts General Hospital & Brigham and Women's Hospital, Harvard University, Boston, Mass (A.A.D., R.W.R., C.J.S., J.D.R., A.B.P.); Departments of Medical Imaging and Neurosurgery, Neurovascular Centre, St. Michael's Hospital, Toronto, ON, Canada M5B 1W8 (A.A.D., N.M.C., T.R.M., V.M.P.); Departments of Neurologic Surgery & Radiology, Mayo Clinic, Rochester, Minn (S.G., H.K., R.K.); Cooper Neurologic Institute, Cooper University Hospital, Cooper Medical School of Rowen University, Camden, NJ (J.E.S., H.S., J.K., A.J.T., A.G.); Departments of Radiology & Neurology, Boston Medical Center, Boston, Mass (M.A., P. Klein, T.N.N.); Department of Interventional Neuroradiology, Stanford Medical Center, Palo Alto, Calif (J.J.H.); Department of Neurosurgery, Thomas Jefferson University, Philadelphia, Pa (K.E.N., A.A., S.I.T., P.J.); Department of Neurosurgery and Interventional Neuroradiology, Louisiana State University, Shreveport, La (H.A.S., B.M., N.A., H.H.C.S.); Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (L.M., J.F. T.D.F.); Department of Neurology, Hôpital Civil Marie Curie, Charleroi, Belgium (A.D., F.B.); Department of Neuroradiology, University Hospital of Limoges, Université de Limoges, Limoges, France (G.F., A.R., S. Saleme, C.M.); Department of Radiology, Division of Neurointerventional Radiology, University of Massachusetts Medical Center, Worcester, Mass (A.L.K., A.S.P.); Department of Neuroradiology, Sana Kliniken, Lübeck GmbH, Lübeck, Germany (C.D.); Department of Neurosurgery, University of Texas Medical Branch, Galveston, Tex (P.T.K., M.C.); Department of Interventional Neuroradiology, Bordeaux University Hospital, Bordeaux, France (G.M., J.B., X.B.); Department of Neurology, Bordeaux University Hospital, Bordeaux, France (I.S.); Department of Neurology, University of Massachusetts Chan Medical School, Worcester, Mass (S.N., N.H.); Department of Psychiatry, University of Massachusetts Chan Medical School, Worcester, Mass (N.H.); Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass (N.H.); Department of Neurosurgery, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan (T.O., S.D.); Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (L.L.L.Y., B.Y.Q.T.); Department of Medicine, Division of Neurology, National University Hospital, Singapore (B.Y.Q.T.); Department of Neurology, UTHealth McGovern Medical School, Houston, Tex (J.C.M.G., S.S.M.); Interventistica Neurovascolare, Ospedale Careggi di Firenze, Florence, Italy (S. Sheth, L.R., C.C.); Department of Neurologic Surgery, Division of Stroke and Endovascular Neurosurgery, Keck School of Medicine, University of Southern California, Los Angeles, Calif (A.M.); Department of Endovascular Neurosurgery and Neuroradiology, Rutgers University New Jersey Medical School in Newark, Newark, NJ (P. Khandelwal); Department of Neurosurgery, Westchester Medical Center at New York Medical College, Valhalla, NY (A.B.); Department of Neuroradiology, Pitié-Salpêtrière Hospital, GRC BioFast, Sorbonne University, Paris, France (F.C., M.E., K.P.); Neurology Department, Faculty of Medicine, Tanta University, Egypt (M.E.); UOSA Neuroradiologia Interventistica, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, Italy (I.V., A.P., A.M.A.); Department of Diagnostic and Interventional Neuroradiology, Centro Hospitalar Universitário do Porto, Porto, Portugal (J.P.F.); Department of Neurology, Centro Hospitalar Universitário do Porto, Porto, Portugal (R.V.); Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, Calif (M.Q.C., N.R.G.); Department of Vascular and Interventional Neuroradiology, Universitätsklinikum Heidelberg, Heidelberg, Germany (M.A.M., J.J., C.W.); Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier University Medical Center, Montpellier, France (V.C., R.A.R.); Department of Neurology, Gui de Chauliac Hospital, Montpellier University Medical Center, Montpellier, France (A.t.S.); Department of Radiology, Division of Neuroradiology, Johns Hopkins Medical Center, Baltimore, Md (V.Y.); Department of Neurology, University of Cincinnati Medical Center, Cincinnati, Ohio (P.H., L.M.C., Y.A.); Department of Interventional Neuroradiology, Nancy University Hospital, Nancy, France (B.G.); INSERM U1254, IADI, Université de Lorraine, Nancy, France (B.G.); Department of Radiology, Section of Interventional Neuroradiology, University Medical Center Münster, Münster, Germany (C.P.S.); Departments of Neurology & Neurosurgery, Christian Doppler Clinic, Paracelsus Medical University, Salzburg, Austria (C.H., M.K.O., C.J.G.); Department of Neurology, Sin-Lau Hospital, Tainan, Taiwan (C.Y.H.); UCLA Stroke Center and Department of Neurology Department, University of California Los Angeles, Los Angeles, Calif (D.S.L.); Department of Medicine, Division of Neurology, The Ottawa Hospital, Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Ontario, Canada (I.T., R.F.); Department of Diagnostic and Interventional Neuroradiology, Erasme University Hospital, Brussels, Belgium (B.L.).

Article Synopsis
  • * Data from 670 patients revealed that while IVT may improve some outcomes, such as higher chances of achieving a modified Rankin Scale score of 0-2 in univariable analysis, this benefit was not consistently observed in more rigorous multivariable analyses.
  • * Overall, the findings suggest that adjunctive IVT may not significantly enhance clinical outcomes or safety compared to MT alone for this patient population.
View Article and Find Full Text PDF

Background: Glioblastoma multiforme (GBM) is an aggressive type of brain tumor that is difficult to remove surgically. Research suggests that substances from saffron, namely crocetin and crocin, could be effective natural treatments, showing abilities to kill cancer cells.

Methods: Our study focused on evaluating the effects of crocetin on glioma using the U87 cell line.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the relationship between alcohol consumption, a specific genetic variant (rs199347), and DNA methylation levels related to the glycoprotein GPNMB, which is linked to Parkinson's disease (PD).
  • Genetic and DNA methylation data were analyzed from 1,357 participants in the Taiwan Biobank, focusing on the interactions between the genetic variant and alcohol consumption in relation to methylation levels.
  • Findings indicate that alcohol consumption in individuals with the rs199347 GG genotype was associated with lower methylation of cg17274742, potentially increasing the expression of the GPNMB gene and posing a higher risk for PD.
View Article and Find Full Text PDF

Insecticide resistance and characteristics of mutations related to target site insensitivity of diamondback moths in Taiwan.

Pestic Biochem Physiol

August 2024

Master (M.S.) Program for Plant Medicine, National Taiwan University, Taipei City 10617, Taiwan; Department of Entomology, National Taiwan University, No.1, Sec. 4, Roosevelt Rd., Taipei City 10617, Taiwan. Electronic address:

Diamondback moth (DBM, Plutella xylostella) is the most significant pest of cruciferous vegetables as they rapidly develop high-level resistance to many insecticides. Monitoring DBM susceptibility and target-site mutation frequency is essential for pest control. In this study, 10 insecticides were tested on 11 field populations.

View Article and Find Full Text PDF

Hydrogen peroxide (HO) production via oxygen (O) reduction reaction (ORR) in pure water (HO) through graphitic carbon nitrides (g-CN)-based piezo-photocatalysts is an exciting approach in many current studies. However, the low Lewis-acid properties of g-CN limited the catalytic performance because of the low O adsorption efficacy. To overcome this challenge, the interaction of g-CN precursors with various solvents are utilized to synthesize g-CN, possessing multiple nitrogen-vacant species via thermal shocking polymerization.

View Article and Find Full Text PDF

Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in treatment-naïve and treatment-experienced people with HIV: Findings from the Asia cohort of the BICSTaR study.

J Microbiol Immunol Infect

October 2024

Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan; Department of Tropical Medicine and Parasitology, National Taiwan University College of Medicine, Taipei, Taiwan; Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address:

Background: The ongoing, observational BICSTaR (BICtegravir Single Tablet Regimen) cohort study is evaluating real-world effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people with HIV across 14 countries over 24 months. We present 12-month data from the BICSTaR Asia cohort.

Methods: Data were pooled from retrospective and prospective cohorts of antiretroviral therapy (ART)-naïve (hereafter, TN) and ART-experienced (hereafter, TE) people with HIV (aged ≥21 years) receiving B/F/TAF in routine clinical care in the Republic of Korea, Singapore, and Taiwan.

View Article and Find Full Text PDF

To assess the effects of hydroxysafflor yellow A (HSYA) on ultraviolet A (UVA)-induced damage in HaCaT keratinocytes. HaCaT keratinocytes were UVA-irradiated, and the effects of HSYA on cell viability, reactive oxygen species (ROS) generation, lipid peroxidation, and messenger (m)RNA expression were measured. mRNA expressions of matrix metalloproteinase (MMP)-1, MMP-2, MMP-9, and cyclooxygenase (COX)-2 were determined by a real-time polymerase chain reaction (RT-PCR).

View Article and Find Full Text PDF

Drug-resistant efflux pumps play a crucial role in bacterial antibiotic resistance. In this study, potential efflux pump inhibitors (EPIs) with a diphenylmethane scaffold were screened and evaluated against drug-resistant . Twenty-four compounds were docked against the drug-binding site of multidrug transporter AcrB, and 2,2-diphenylethanol (DPE), di--tolyl-methanol (DPT), and 4-(benzylphenyl) acetonitrile (BPA) were screened for their highest binding free energy.

View Article and Find Full Text PDF

Sacral Magnetic Neuromodulation with Intermittent Theta Burst Waveform Enhances Overactive Bladder: In Vivo Study.

Biomed J

July 2024

Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan; School of Biomedical Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan; School of Gerontology and Long-Term Care, College of Nursing, Taipei Medical University, Taipei 11031, Taiwan. Electronic address:

Background: The current treatment options for overactive bladder (OAB) continue to pose challenges for refractory cases and may involve invasive procedures. To assess the potential benefit of non-invasive repetitive peripheral magnetic stimulation (rPMS) on sacral roots using intermittent theta burst stimulation (iTBS) as treatment option for OAB. The study involved a total of 33 rats, which were divided into three different experimental phases.

View Article and Find Full Text PDF

Aim: We attempted to test the influences of cyclin dependent kinase inhibitor 2B antisense RNA 1 (CDKN2B-AS1) gene polymorphisms on the susceptibility to Diabetic retinopathy (DR).

Methods: Five single-nucleotide polymorphisms (SNPs) of the CDKN2B-AS1 gene, rs564398, rs1333048, rs1537373, rs2151280, and rs8181047 were examined in 280 DR cases and 455 DR-free diabetic controls.

Results: Among these loci tested, we demonstrated that diabetic carriers of at least one polymorphic allele (G) of rs2151280 (AG and GG; AOR, 1.

View Article and Find Full Text PDF
Article Synopsis
  • Researchers analyzed data from 952 patients, categorizing their adherence based on the proportion of days covered, showing that most patients (86.1%) had high adherence (PDC ≥ 90%).
  • The research concluded that lower adherence levels (80-<90% and <80%) did not significantly increase the risk of treatment discontinuation compared to high adherence, indicating that factors like virologic failure were not directly tied to adherence levels.
View Article and Find Full Text PDF
Article Synopsis
  • Study Overview
  • : This research is a phase II randomized trial comparing the effectiveness and safety of pegylated liposomal doxorubicin (PLD) versus epirubicin as adjuvant chemotherapy for stage I-II HER2-negative breast cancer.
  • Methods and Results
  • : A total of 256 patients were divided into two groups, with results showing no significant difference in 5-year disease-free survival (DFS) and overall survival (OS) rates between PLD and epirubicin. However, the PLD group experienced less severe side effects and improved quality of life (QoL) during treatment.
  • Conclusion
  • : Both treatment regimens showed comparable efficacy and safety, but the
View Article and Find Full Text PDF

Cellulose acetate-coated capacitive sensor for determining carbon-cycle enzymes activity and as a microbial Indicator for soil health.

Sci Total Environ

October 2024

Department of Biomechatronics Engineering, College of Bioresources and Agriculture, National Taiwan University, Taipei, Taiwan. Electronic address:

This study demonstrates cellulose acetate (CA)-coated screen-printed carbon electrodes (SPCEs) for soil microbial activity detection. A capacitive sensor design utilizes a coated CA layer for effective insulation in electrolytes, eliminating the need for additional signal protection. Optimization involved comparing spin and dip coating methods, with a one-layer 10-second dip coating identified as the best balance between quality and yield.

View Article and Find Full Text PDF

Refining the understanding of EPA's role in episodic migraine: A response to methodological considerations.

Brain Behav Immun

October 2024

Mind-Body Interface Research Center (MBI-Lab), China Medical University Hospital, Taichung, Taiwan; Institute of Psychiatry, King's College London, London, UK; College of Medicine, China Medical University, Taichung, Taiwan; An-Nan Hospital, China Medical University, Tainan, Taiwan. Electronic address:

View Article and Find Full Text PDF

Background And Aim: Primary liver cancer, particularly hepatocellular carcinoma (HCC), represents a substantial global health challenge. Although immune checkpoint inhibitors are effective in HCC treatment, several patients still experience disease progression. Interleukin-1 (IL-1) regulates immunity and inflammation.

View Article and Find Full Text PDF

Dienogest treatment in women with endometriosis: A retrospective cohort study in Taiwan.

Taiwan J Obstet Gynecol

July 2024

Department of Obstetrics and Gynecology, Cathay General Hospital, Taipei, Taiwan. Electronic address:

Objective: To assess the treatment efficacy of dienogest specifically in the Taiwanese population with endometriosis.

Materials And Methods: Eighty-eight patients diagnosed with endometriosis receiving at least 3 months of dienogest 2 mg once daily, from January 2018 to June 2022, were enrolled. They were divided into two groups: surgery group and non-surgery group.

View Article and Find Full Text PDF

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a complex chronic pain disorder with an elusive etiology and nonspecific symptoms. Although numerous animal models with phenotypes similar to human disease have been established, no available regimen can consistently alleviate clinical symptoms. This dilemma led us to question whether current animal models adequately represent IC/BPS.

View Article and Find Full Text PDF

One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial.

Clin Microbiol Infect

November 2024

Department of Biological Science and Technology, National Chiao Tung University, Hsinchu, Taiwan; Institute of Bioinformatics and Systems Biology, National Chiao Tung University, Hsinchu, Taiwan; Center for Intelligent Drug Systems and Smart Bio-devices, National Chiao Tung University, Hsinchu, Taiwan.

Objectives: The weekly rifapentine plus isoniazid for 3 months (3HP) improves completion rate of latent tuberculosis infection treatment, but flu-like symptoms are common. The novel 1HP regimen, involving daily rifapentine plus isoniazid for 28 days, has demonstrated low toxicity in HIV-infected populations. We aimed to investigate whether 1HP has a lower incidence rate of systemic drug reaction (SDR) compared with 3HP during treatment in non-HIV populations.

View Article and Find Full Text PDF

To observe the clinical outcomes of patients diagnosed with metastatic breast cancer undergoing Trastuzumab Deruxtecan (T-DXd) therapy in a real-world setting. The study retrospectively reviewed and collected medical data from 13 patients at Shin Kong Wu Ho-Su Memorial Hospital who underwent T-DXd treatment over a period from April 2022 to June 2023. Demographics, pathological characteristics, treatment patterns, and outcomes were descriptively analyzed.

View Article and Find Full Text PDF

Adsorption-driven reverse osmosis separation of ethanol/water using zeolite nanosheets.

Phys Chem Chem Phys

July 2024

Department of Chemical Engineering, National Taiwan University, No. 1, Sec. 4, Roosevelt Road, Taipei 10617, Taiwan.

Developing more energy-efficient and cost-effective membrane processes for the separation of ethanol and water represents a strategically important direction to facilitate the production of renewable biofuels. In this study, by employing state-of-the-art molecular simulations, the potential of zeolite nanosheets as reverse osmosis (RO) membranes in ethanol/water separation is investigated. These materials are predicted to offer unprecedentedly high fluxes and more importantly, the ethanol-to-water separation factor can be as large as approximately 800 if the structure is meticulously selected.

View Article and Find Full Text PDF

Association of Body Mass Index and Parkinson Disease: A Bidirectional Mendelian Randomization Study.

Neurology

August 2024

From the Université Paris-Saclay (C.D., P.-E.S., B.P., A.E.), UVSQ, Inserm, Gustave Roussy, CESP, Villejuif, France; Centre for Genetic Epidemiology (A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, and Department for Neurodegenerative Diseases (C.S., K.B., T.G.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., K.B., T.G.), Tubingen; Center for Human Genetics (S.G.), Universitatsklinikum Giessen und Marburg, Germany; Department of Public Health (P.-C.L.), National Cheng Kung University, Tainan, Taiwan; Translational Neuroscience (P.M., D.B., R.K.), Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-Belval; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Molecular Genetics Section (A.B.S., D.H., C.E.), Laboratory of Neurogenetics, and Center for Alzheimer's and Related Dementias (A.B.S.), NIA, NIH, Bethesda, MD; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Nathan, Australia; Department of Neurology (A.A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Tanz Centre for Research in Neurodegenerative Diseases (E.A.R., A.E.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.E.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.E.L.), University of Toronto; Krembil Brain Institute (A.E.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic (P.T.), Tartu University Hospital, Estonia; Department of Neurologie (S.L., A.B., J.-C.C.), Institut du Cerveau-Paris Brain Institute-ICM, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, Sorbonne Université; Assistance Publique Hôpitaux de Paris (J.-C.C.), Department of Neurology, CIC Neurosciences; Univ. Lille (M.-C.C.-H., E.M.), Inserm, CHU Lille, UMR-S 1172-LilNCog-Centre de Recherche Lille Neurosciences & Cognition, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Greece; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia; 1st Department of Neurology (L. Stefanis, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens; Center of Clinical Research, Experimental Surgery and Translational Research (L. Stefanis), Biomedical Research Foundation of the Academy of Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital, Rome; Department of Clinical and Molecular Medicine (S.P.), University of Rome; Department of Biomedical Sciences (L. Straniero), Humanitas University, Milan; Parkinson Institute (A.L.Z.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano; Parkinson Institute (G.P.), Fontazione Grigioni-Via Zuretti, Milan; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Monza; Department of Medicine and Surgery and Milan Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Milano; Institute for Biomedical Research and Innovation (G.A.), National Research Council, Cosenza; Institute of Neurology (A.Q.), Magna Graecia University; Institute of Molecular Bioimaging and Physiology National Research Council (M.G.), Catanzaro, Italy; Department of Integrative Physiology and Bio-Nano Medicine (H.M., A.N.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Neurology (P.K., R.K.), Centre Hospitalier de Luxembourg; Department of Neurology (B.P.C.V.D.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Nijmegen, Radboud University Medical Centre, the Netherlands; Department of Neurology (M.T., L.P.), Oslo University Hospital, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit (E.T.), Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) (E.T.); Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.-F.), Terrassa; Movement Disorders Unit (P.P., M.D.-F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), and Department of Neuroscience (C.R., A.C.B.), Karolinska Institutet, Stockholm; Department of Clinical Sciences Lund (A.P., C.H.), Neurology, Skåne University Hospital, Lund University, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine (K.E.M.), Health and Life Sciences, Queens University, Belfast; Department of Clinical and Movement Neurosciences (M.M.T.), UCL Queen Square Institute of Neurology, University College London, United Kingdom; Department of Neurology (D.K., L.F.B.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universität München; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.); German Center for Neurodegenerative Diseases (DZNE) (L.F.B.), Munich, Germany; Department of Neurology (M.F.), McKnight Brain Institute, University of Florida, Gainesville; Parkinson's Research Clinic (R.K.), Centre Hospitalier de Luxembourg; and Transversal Translational Medicine (R.K.), Luxembourg Institute of Health (LIH), Strassen.

Article Synopsis
  • The study investigates the relationship between body mass index (BMI) and Parkinson's disease (PD) using a method called Mendelian randomization to determine if higher genetically predicted BMI is linked to a lower incidence of PD.
  • Researchers analyzed genetic data from large groups of individuals, including over 800,000 for BMI and nearly 29,000 for PD, focusing on factors like age, disease duration, and gender to examine the associations.
  • Results indicated an inverse relationship between genetically predicted BMI and PD, particularly among younger participants and women, suggesting that lower BMI may be associated with a higher risk of developing Parkinson's disease.
View Article and Find Full Text PDF